Stock Ratings / Health Care / MSLE / financials

MENS (33) RNA (55) NBP (38) MGNX (31) ⌘ Pro Terminal →

Satellos Bioscience Inc. (MSLE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$6.70 -1.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.67

Satellos Bioscience Inc. (MSLE) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY) →

ROARABLE D+ • SELL / AVOID Cap $144.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MSLE Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MSLE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, Satellos Bioscience Inc. (NASDAQ: MSLE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 58/100 at a spot price of $6.70 (-1.69% 1D, market cap $144.6M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, MSLE ranks #202 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MSLE compare to MENS and RNA in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MSLE carries a Roarable D+ (58/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, MENS (Jyong Biotech Ltd.) holds a E grade (33/100 RQD, P/E N/A, ROIC -28.8%, cap $142.9M) and RNA (Atrium Therapeutics Inc.) posts a D+ grade (55/100 RQD, P/E N/A, ROIC —, cap $141.3M). Among the 5-stock peer group, MSLE leads on earnings multiple (N/A) while MENS leads on capital efficiency (-28.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MSLE?

▼

For Satellos Bioscience Inc. (MSLE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #202 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $6.67 (-0.49%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.1% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 58/100 (D+) historically posted market-perform odds over rolling 90-day windows (+0.0% avg 90D alpha vs SPY • 52.7% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D+

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE+0% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MSLE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (58/100 Composite)

🔍 WHY MSLE SCORES 58/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (22% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Macro Regime Fit+13/20 pts (22% of score)

FRED Regime × Technicals: 17% of 52W Range • RSI-14 at 41.2 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade B-$7.17-10.2% Next Q

Q2 (-2Q)

Grade C+$6.44+1.6% Next Q

Q3 (-1Q)

Grade C$6.54+2.4% Next Q

Current

Grade D+$6.70+0% Hist 90D α

Trajectory: B- (66) → D+ (58)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MSLE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 58/100 (D+) score, MSLE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($8.22) or 200D SMA ($8.48) invalidates the momentum regime and cuts Target Base ($6.70) toward Bear Floor ($5.23).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MSLE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “MSLE Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 58%NO 42%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How MSLE Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$4.0M (0.1% FCF Margin)

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MSLE)

✓Walkthrough of MSLE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

MSLE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -19.86%▼ DESCENDING CHANNEL

2026-11-02O $6.75H $6.75L $6.70C $6.70VOL 196

RES: $10.28SUP: $6.13SMA50: $8.22SMA200: $8.48

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MSLE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MSLE Butterfly Map → + Track MSLE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on MSLE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MSLE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for MSLE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MSLE)

Health Care Rank #202 of 1016 ⚔️ MENS vs MSLE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MSLE vs. MENS, RNA, NBP, MGNX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Satellos Bioscience Inc. (MSLE) ranks #202 by composite RQD confidence (58/100, grade D+) and #614 by equity capitalization ($144.6M). Within this direct 5-issuer industry benchmark cohort, MSLE leads on earnings valuation at N/A trailing P/E, while MENS leads on capital efficiency and profitability with -28.8% ROIC and — gross margin. MSLE currently leads its immediate peer cohort in composite quantitative strength at 58/100 (D+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
MSLE ACTIVE Satellos Bioscience Inc.	D+	58/100	—	—	—	-1.69%	$144.6M	Benchmark Subject
MENS Jyong Biotech Ltd.	E	33/100	—	—	-28.8%	0.00%	$142.9M	/mens-vs-msle →
RNA Atrium Therapeutics Inc.	D+	55/100	—	—	—	+0.12%	$141.3M	/rna-vs-msle →
NBP NovaBridge Biosciences	D-	38/100	—	—	-35.0%	-1.24%	$139.6M	/nbp-vs-msle →
MGNX MacroGenics Inc.	E	31/100	—	96.0%	-35.0%	+0.84%	$151.6M	/mgnx-vs-msle →

2. MSLE Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Satellos Bioscience Inc. (MSLE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $144.6M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. MSLE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MSLE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does MSLE compare to MENS and RNA in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for MSLE?

Where is MSLE trading relative to its 50-day, 200-day, and 52-week technical levels?

MSLE last traded at $6.70 (-1.69% on volume of 30,768 shares), positioning the stock -18.49% below its 50-day simple moving average ($8.22) and -20.99% below its 200-day simple moving average ($8.48). Across its 52-week range of $5.30 to $13.40, MSLE sits at the 17.3% percentile with a 14-day RSI of 41.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.86 to $7.54).

MSLE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Satellos Bioscience Inc. (MSLE)?

In Trailing 12 Months, MSLE converted $4.0B of revenue into a 52% gross margin, 27% operating margin, and $4.0M in free cash flow (0.1% FCF margin).

Direct Sub-Reports: MSLE RQD Cockpit MSLE 12M Forecast MSLE Earnings & Move MSLE Dividends & DRIP MSLE Insiders & 13F MSLE Whale Options MSLE Profit Sankey MSLE News & Why

ROARABLE RATING BRIEF • RQD 58/100 (D+) ✓ STAGE-C NUMBER FIREWALL VERIFIED

MSLE — Satellos Bioscience Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T14:17:55Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, MSLE scores 58 out of 100, a D+ grade labeled "Roarable Sell — Weak Fundamentals / Trim." The five pillars are:

Fundamental Cash Engine: 12 / 20. The RQD rating reports ROIC of 0% and FCF yield of 0%. This pillar is the weakest signal in the rating, indicating that the source data shows no measurable return on invested capital or free-cash generation.
Whale 13F Flow: 11 / 20. This pillar covers institutional accumulation and options positioning. The score is below midpoint, but the source data provides no further breakdown of holdings or flows.
Insider Conviction: 9 / 20. Per the rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. It is the lowest-scoring pillar, which the rating treats as a weak signal of insider conviction.
Macro Regime Fit: 13 / 20. The rating reports a beta of 1.0 and notes sector sensitivity. This is a moderate score with no further detail in the source data.
Forensic Balance Sheet: 13 / 20. The rating cites an Altman Z of 2.5, a Piotroski F of 6/9, and a Debt/Equity of 0.5. These figures sit in a middling range that neither clearly signals distress nor clearly signals strength.

For a prospective investor, the combined picture is one of weak cash-generation metrics, lukewarm institutional signals, and the weakest insider-conviction reading, offset partially by a moderate balance-sheet profile. The rating's own verdict is to trim rather than accumulate. The upside case rests on factors the source data does not quantify, since no earnings, revenue, or valuation multiples are available to support a fundamental re-rating. Valuation cannot be assessed against earnings because P/E and EPS are not available in source data.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed, six items relate to MSLE:

Market wire (yellow): A Yahoo Finance UK item covering market action and institutional positioning, with no specific event described.
Market wire (yellow): A Stock Titan item announcing one-on-one meetings with Satellos leaders in Boston and London this November.
Market wire (yellow): A MarketBeat item reporting a "Moderate Buy" consensus rating from Wall Street analysts.
Risk watch (red): A MarketBeat item reporting that the rating was cut to Strong Sell at Zacks Research. This is the only red-flag item in the feed.
Market wire (yellow): A report stating the stock slid 5.56% to $6.46, pulling back toward lower support.
Market wire (yellow): A Stock Titan item stating Harvard and Stanford scientists will advise Satellos on how aging affects tissue repair.

The butterfly supply-chain graph reports no supply-chain links and no proprietary signals. The news feed therefore contains a conflict: a "Moderate Buy" consensus is reported alongside a Strong Sell rating cut from Zacks Research, and these cannot be reconciled from the source data.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, supply chain is NONE, with no upstream or downstream links and no sector-correlation entries. The graph is therefore empty for MSLE, and second-order ripple analysis cannot be performed from the source data. A prospective investor should note that no supply-chain dependencies, customer concentration, or sector correlations are documented here.

Open Questions

What are the company's reported revenue, operating income, net income, and free cash flow, given that no financial periods are provided?
What explains the conflict between the reported "Moderate Buy" consensus and the Zacks Research cut to Strong Sell?
What are the lead product candidates and their clinical or regulatory stages, since the profile describes only a sector classification?
What insider, 13F institutional, and Congressional trades have occurred, given that the holders section is empty?
What are the valuation multiples (P/E, EV/EBITDA) that would allow comparison with peers, given that all are unavailable?

MSLE Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Satellos Bioscience Inc. (MSLE) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MSLE Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance UK • 7h ago

Satellos Bioscience Inc. (MSCL.TO) stock price, news, quote and history

Yahoo Finance UK report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 10h ago

One-on-one meetings with Satellos leaders will be available in Boston and London this November.

Stock Titan report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE MarketBeat • 13h ago

Satellos Bioscience Inc. (NASDAQ:MSLE) Stock Now Rated "Moderate Buy" by Wall Street Analysts

MarketBeat report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH MarketBeat • 16h ago

Satellos Bioscience (NASDAQ:MSLE) Stock Rating Cut to Strong Sell at Zacks Research

MarketBeat report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE https://www.siam.in/ • 19h ago

Satellos Bioscience (MSLE) Slides 5.56% to $6.46, Pulling Back Toward Lower Support - Virgin POC

https://www.siam.in/ report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 22h ago

Harvard and Stanford scientists will advise Satellos on how aging affects tissue repair.

Stock Titan report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Boston and London host Satellos (MSLE) investor appearances on November 9 and 18–19.

Stock Titan report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

Six advisers join Satellos Bioscience (MSLE) to guide research on aging and regeneration.

Stock Titan report covering Satellos Bioscience Inc. (MSLE) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MSLE Bull vs. Bear Conversation Board — What's Your Call at $6.70?

🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MSLE 🐻 50% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST 🎯 Target: $7.37 (+8.1%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is MSLE (D+ • RQD 58/100) a Buy at $6.82?

Welcome to the MSLE (Satellos Bioscience Inc.) Roar Pit. Current RQD Composite is 58/100 (Roarable Sell — Weak Fundamentals / Trim) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

BE BearTrap_Alert Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $5.12 (-24.9%)

Spot @ $6.82

Pump the brakes on MSLE — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on MSLE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Satellos Bioscience Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

CA CashFlowKing Verified K Arena Trader 🐂 BULLISH 🎯 Target: $8.73 (+28.0%)

Spot @ $6.82

MSLE cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on MSLE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $6.82 (52-wk range $6.06 - $7.56), any beat on forward guidance forces shorts and underweight funds to chase.